ZELRIBO

Serial Number 98848247
661

Registration Progress

Application Filed
Nov 12, 2024
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Non-Final Action E-Mailed
Due: Aug 07, 2025 4 days

Trademark Image

ZELRIBO

Basic Information

Serial Number
98848247
Filing Date
November 12, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
661
Status Date
Jul 3, 2025
Application
Pending
Classes
005

Rights Holder

PRG S&Tech Inc.

03
Address
9F, 252 Geumjeong-ro, Geumjeong-gu
Busan 46274
KR

Ownership History

PRG S&Tech Inc.

Original Applicant
03
Busan KR

Legal Representation

Attorney
Sangwon Kim

USPTO Deadlines

Next Deadline
4 days remaining
Non-Final Action E-Mailed
Due Date
August 07, 2025
Extension Available
Until November 07, 2025

Application History

9 events
Date Code Type Description Documents
Jul 3, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 3, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 3, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 7, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 7, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
May 7, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 15, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 12, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 12, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for symptom improvement and treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) patients for medical purposes; pharmaceutical products for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS); medicinal preparations for symptom improvement and treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) for human purposes; pharmaceutical products for the treatment of progeria; pharmaceutical preparations for the treatment of disorders of the endocrine system; pharmaceutical preparations acting on the central nervous system for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS)

Classification

International Classes
005